Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188282 | 1.00 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL2188279 | 1.00 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL4920966 | 0.85 | KMT2A (0.64) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL6099597 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL9025236 | 0.85 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL6099592 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL6099600 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL6098746 | 0.85 | SMN1; SMN2 (0.74) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL7898746 | 0.85 | SMN1; SMN2 (0.74) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 | |
| SCHEMBL7898749 | 0.85 | SMN1; SMN2 (0.74) | ALDH1A1SMN1; SMN2TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361246-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | Pfizer Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | disclosed |
| WO-2010038167-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | GRIK5, GABRE, GRIK2 | ALDH1A1 1118/4885SMN1; SMN2 2115/4885TDP1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.